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ABSTRACT 
Background: Of the US Food and Drug Administration (FDA)-approved 
5-hydroxytryptamine type 3 (5-HT3)-receptor antagonists, dolasetron, ondan- 
setron, granisetron, and palonosetron, only dolasetron and palonosetron have a 
precaution i their FDA labeling concerning corrected QT interval (QTc) prolonga- 
tion. At FDA-approved oses, QTc prolongation has been observed in clinical trials 
with some 5-HT3-receptor antagonists (however, palonosetron has been only 
recently approved, with few published clinical data available). However, due to 
patient exclusion criteria, such trials with 5-HT3-receptor antagonists may have 
failed to examine the risk of these agents in "real world" patients with cancer. 
Objective: The aim of this analysis was to assess the potential risk for 
selected cardiac adverse vents associated with dolasetron, ondansetron, and 
granisetron use. 
Methods: The FDA combined Spontaneous Reporting System/Adverse Event 
Reporting System database was analyzed. The process of analyzing such a data- 
base for early warnings of potential hazards is known as signal generation. The sta- 
tistical technique proportional reporting ratio (PRR) was used to aid detection of 
a potential signal within the database. PRR is the observed proportion of a given 
adverse vent for the drug of interest (the number of events of interest for the drug 
divided by the total number of reports for the drug) divided by the expected pro- 
portion. Through the third quarter of 2002, the database was searched using the 
preferred term electrocardiogram qt corrected interval prolonged. 
Results: One, 3, and 0 cases were reported for dolasetron, ondansetron, and 
granisetron, respectively. The number of cases did not satisfy 1 of the 3 criteria 
we utilized to define a potential signal, the 3 criteria being: 3 or more reported 
cases of the adverse vent, a PRR value of at least 2, and a ~2 value of >4. As this 
term may be unlikely to be reported, the database was also searched using the 
term ventricular arrhythmias and cardiac arrest. The PRR, used as a parameter 
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to detect a potential signal within the database, was 3.23, 1.31, and 1.13 for 
dolasetron, ondansetron, and granisetron, respectively. The number of ob- 
served ventricular arrhythmias and cardiac arrests was ~3-fold higher with 
dolasetron compared with the expected value (calculated by dividing the indi- 
vidual agent's total number of events reported by the proportion of adverse 
events for all agents combined). The results for dolasetron fulfilled the criteria 
we used to define a potential signal. 
Conclusions: This analysis detected a potential signal for ventricular arrhyth- 
mias and cardiac arrest with dolasetron, but not with ondansetron or grani- 
setron. However, there are limitations of a PRR analysis, which include only 
measuring cases that have been reported, providing relative frequencies in- 
stead of actual rates, and not providing information on the severity of adverse 
events or causal relationships. In addition, our analysis does not include con- 
sideration of concomitant medications, and only 2 search terms were used. 
Errors in identifying potential signals may also include confounding factors, 
such as the underlying disease, potential confusion with reporting under trade 
and generic names, and potential multiple reporting of the same case. (Curr 
Ther Res Clin Exp. 2005;66:409-419) Copyright © 2005 Excerpta Medica, Inc. 
Key words: antiemetic, 5-hydroxytryptamine type 3 antagonists, cardio- 
vascular events. 
INTRODUCTION 
The electrocardiogram (ECG) QT interval is often transformed (normalized) 
into a heart rate-independent "corrected" value known as the corrected QT 
(QTc) interval. Prolongation of the cardiac QTc interval is a risk factor for sud- 
den cardiac death 1and torsades de pointes, a potentially fatal cardiac arrhyth- 
mia. A cutoff value of 440 ms for QTc prolongation is the generally used value 
in international literature. 2 
Cardiac sodium and potassium channels are both important determinants of 
the ECG. Of the 5-hydroxytryptamine type 3 (5-HT3)-receptor antagonists ap- 
proved by the US Food and Drug Administration (FDA) for use in prophylaxis 
of chemotherapy-induced nausea nd vomiting, dolasetron, ondansetron, and 
granisetron have the ability to block these cardiac sodium and potassium chan- 
nels in vitro with varying potency. 3 Palonosetron, another agent approved by 
the FDA, has not been tested in this in vitro model. 
Clinical reports have demonstrated that dolasetron use is associated with 
prolongation of the QTc interval, 4-16 and, although rare, certain studies have 
also associated ondansetron use with QTc interval prolongation. 4,12,17 None- 
theless, these changes with both dolasetron and ondansetron were considered 
clinically insignificant by the study investigators. The ECG interval prolonga- 
tions, including QTc interval, observed following the administration of ondan- 
setron 32 mg IV in patients receiving cisplatin-based chemotherapy were clini- 
cally asymptomatic, and the incidence of cardiovascular dverse vents that 
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might be deemed related to these ECG changes was low. 4 Similarly, the QTc in- 
terval prolongation observed in patients treated with ondansetron 32 mg IV 
or 8 mg PO BID following moderately emetogenic chemotherapy was also asymp- 
tomatic and did not require treatment. 12 Although use of ondansetron 32 mg IV 
was associated with a significantly onger postdose QTc interval compared with 
either vehicle or granisetron 10 pg/kg IV regimens in healthy adults, these 
changes were transient and not associated with clinical symptoms. 17
Granisetron use does not appear to significantly prolong the QTc interval. 7,17-25 
One study has reported some ECG changes associated with the use of grani- 
setron 50 pg/kg IV in patients undergoing repeat courses of chemotherapy with 
multiple chemotherapy agents. 26 However, there were no reports of QTc inter- 
val prolongation, and the authors did not conclude that granisetron had a clini- 
cally significant effect on the heart. 
The effects of dolasetron, ondansetron, and granisetron use on the QTc in- 
terval have been compared in some clinical trials. 7,12,17 Dolasetron (1.8 or 
2.4 mg/kg IV) has been reported to produce asignificantly greater increase in QTc 
interval prolongation compared with granisetron (3 mg IV)7 and ondansetron 
(32 mg IV or 8 mg PO BID) 12 in patients with cancer. Furthermore, another vehicle- 
controlled study has demonstrated that the use of IV ondansetron (32 mg 
infused over 15 minutes) is associated with a statistically longer postdose 
QTc interval compared with 2 IV granisetron regimens (10 pg/kg infused over 
5 minutes or 30 seconds); however, the magnitudes of the prolongations were 
deemed unlikely to be clinically meaningful. 17 However, even clinically insignif- 
icant prolongations may be important in patients who already have borderline 
or slight prolongation of their QT interval. 
Dolasetron carries precaution i  its labeling concerning dose-dependent QTc 
prolongation and other ECG interval effects, 27 urging caution in patients who 
have or may develop rolongation of cardiac onduction i tervals, whereas the 
labels of ondansetron 28 and granisetron 29 do not contain a precautionary state- 
ment about QTc prolongation. 
Some of these clinical studies were performed in healthy volunteers 5,6,8,9,I5- 
17,19,20 or in patient populations that exclude elderly oncology patients and/or 
those with certain cardiac comorbidities 4,7,1°-14,18,21,23,24 or receiving certain 
antiarrhythmic medications. 4,7,1°,11,21 Thus, it is postulated that these trials 
did not assess the true risk of these agents in "real world" patients with can- 
cer, who are often older than 65 years, have comorbidities, and/or are taking 
multiple medications. 3°-32 Therefore, the objective of this analysis was to assess 
the risk for selected adverse cardiac events associated with the use of the 
5-HT3-receptor antagonists dolasetron, ondansetron, and granisetron in 
patients in the FDA combined Spontaneous Reporting System and Adverse 
Event Reporting System (SRS/AERS) database. 33The database originates from 
1969 and comprises adverse events reported by health professionals and 
drug manufacturers, who are required by regulation to forward adverse vent 
reports to the FDA. 
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MATERIALS AND METHODS 
Through the third quarter of 2002, the FDA SRS/AERS database was searched using 
the preferred term electrocardiogram qtcorrected interval prolonged for reports 
associated with dolasetron, ondansetron, or granisetron use. The high-level term 
ventricular arrhythmias and cardiac arrest was also used to search the database 
through the third quarter of 2002, as described in the results below. The starting 
null hypothesis was that the 3 agents would have an equal proportion of these 
adverse vents in their event profiles. 
The process of analyzing spontaneous adverse drug reaction reports for early 
warnings of potential hazards is known as signal generation. 34 Generation of a 
potential signal may be a starting point for further investigation. However, the 
question of what constitutes a signal requires certain judgments o be made, such 
as on the number and quality of case reports. 34 The use of statistical nalyses may 
aid this judgment process. In this study, a proportional reporting ratio (PRR) was 
used to aid detection of a potential signal within the database. This statistical tech- 
nique has been used previously to aid detection of signals from spontaneous 
adverse drug reaction reports. 34 The PRR is the observed proportion of a given 
adverse vent for the drug of interest (the number of events of interest for the drug 
divided by the total number of reports for the drug) divided by the expected pro- 
portion. The expected proportion is based on a null hypothesis that predicts no 
relationship between the drug of interest and the adverse vent (eg, ventricuiar 
arrhythmias and cardiac arrest), in which case, the proportion of such adverse 
events for the drug of interest (within its total adverse vent profile) would be the 
same as that for all drugs in the database combined. Therefore, the expected pro- 
portion is the number of events of interest for all other drugs divided by the total 
number of reports for all other drugs. The null value for a PRR is therefore 1, as 
the proportion of observed and expected adverse vents hould be equal. 
A previous tudy using the PRR as a tool for analysis tated that 3 criteria be 
used to indicate apotential signal. 34 We have adopted the same criteria to indicate 
the presence of a potential signal for dolasetron, ondansetron, or granisetron. In
this analysis of the FDA SRS/AERS database, the 3 criteria needed to be present to 
constitute a potential signal (and therefore a potential association between the 
drug of interest and the adverse vent) were: 
• Three or more reported cases of the adverse vent; 
• A PRR value of at least 2; and 
. A ~2 value (the associated statistic for this type of analysis) of >4. 
The PRR for this analysis was calculated using QScan version 2.0 (QED 
Solutions Inc., Houston, Texas). 
RESULTS 
The original search term revealed that 1, 3, and 0 cases of electrocardiogram qt 
corrected interval prolonged were reported to the FDA SRS/AERS database for 
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dolasetron, ondansetron, and granisetron, respectively. This yielded a PRR of 
4.97 for dolasetron, 1.42 for ondansetron, and 0.00 for granisetron. The number 
of cases revealed id not therefore fulfill the signal criteria regarding minimum 
number of reported cases (at least 3) and was too few to evaluate for a poten- 
tial signal with this search term. 34 
Ambulatory patients with cancer arely undergo routine ECG monitoring. It
was thus deemed unlikely that this original search term would be reported as 
an adverse vent of therapy with dolasetron, ondansetron, or granisetron. The 
high-level term ventricular arrhythmias and cardiac arrest was therefore used as 
a surrogate to search the database through the third quarter of 2002. The num- 
ber of observed ventricular arrhythmias and cardiac arrest events was ~3-fold 
higher with dolasetron compared with expected (Table). Using the 3 criteria of 
Evans et a134 as an indication of a signal, a potential signal for ventricular arrhyth- 
mias and cardiac arrest events was detected with dolasetron, but not with either 
ondansetron or granisetron. 34 For dolasetron, all 3 criteria for a potential signal 
were fulfilled: the number of reported cases of the adverse vent was at least 3, 
the PRR value was at least 2, and the ~2 value was >4 (Table). The 3 criteria were 
not fulfilled for either ondansetron or granisetron. 
DISCUSSION 
To determine selected cardiac adverse vents associated with the use of the 
5-HT3-receptor antagonists dolasetron, ondansetron, and granisetron, the FDA 
SRS/AERS database was searched. A PRR is meant o facilitate the early detection 
of safety signals and is used for hypothesis generation. As a means of analysis, 
the PRR has some limitations. Specifically, it measures only cases that have been 
reported, it provides relative frequencies instead of actual rates, and it does not 
provide information concerning the severity of adverse vents or causal rela- 
tionships. Additional imitations of our analysis include that concomitant med- 
Table. Observed and expected incidence of ventricular arrhythmias and cardiac 
arrests associated with the use of dolasetron, ondansetron, and granisetron, 
from analysis of the US Food and Drug Administration combined Spontaneous 
Reporting System/Adverse Event Reporting System database. 33 
Ventricular Arrhythmias and Cardiac Arrests 
Drug Observed, % Expected, % PRR* ~2 
Dolasetron 68 21.1 3.23 104.6 
Ondansetron 289 220.9 1.31 21.0 
Granisetron 109 96.4 1.1 3 1.6 
PRR = proportional reporting ratio. 
*Calculated using QScan version 2.0 (QED Solutions Inc., Houston, Texas). 
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ications were not taken into account, and only 2 search terms were used. Errors 
in identifying potential signals may also include confounding factors, such as 
the underlying disease, potential confusion with reporting under trade and 
generic names, and potential multiple reporting of the same case. Such limita- 
tions necessitate interpretation of the results with caution, but do suggest a
need for further research into the potential signal for ventricular arrhythmias 
and cardiac arrest with dolasetron. 
The analysis revealed a potential signal for ventricular arrhythmias and car- 
diac arrest with dolasetron, but not with either ondansetron or granisetron. A 
possible explanation for our findings may be the differential sodium channel 
blockade by these drugs. Drugs that block sodium channels may produce 
widening of the QRS interval (the phase of the ECG representing ventricular 
depolarization), possibly resulting in ventricular arrhythmias. 3 The active 
metabolites of dolasetron may block sodium channels, a property unrelated to 
its ability to block 5-HT 3 receptors. 27Prolongation of the QTc interval is primari- 
ly due to QRS widening, and dolasetron appears to prolong both depolariza- 
tion and, to a lesser extent, repolarization time. 27 The magnitude and frequency 
of the ECG changes associated with dolasetron use increase with dose (related 
to Cma ~ values of the active metabolite hydrodolasetron). 27 
We hypothesize that the potential signal for ventricular arrhythmias and cardiac 
arrest detected with dolasetron, but not ondansetron or granisetron, may be due 
to the different effects of the 5-HT3-receptor antagonists in blocking cardiac 
sodium channels at the plasma concentrations arising from the therapeutic doses 
required to treat nausea and vomiting. Although granisetron is more effective 
compared with dolasetron/hydrodolasetron and ondansetron i  blocking human 
cardiac sodium channels (hill) (Figure), the plasma concentration calculated to 
result from an IV dose of 40 pg/kg may be insufficient to produce significant 
sodium channel blockade. We calculated plasma concentrations of ~184 nmol/L 
after administration f granisetron 40 pg/kg IV (calculated from prescribing infor- 
mation [P[], 29 using molecular weight [MW] 348.9 and Cma x 64.3 ng/mL after 
administration f a 40-pg/kg IV dose). Thus, it may be even less likely that the 
dose (10 pg/kg) of granisetron approved by the FDA for the prevention of 
chemotherapy-induced nausea and vomiting will produce such a blockade. 
Similarly, plasma concentrations produced following the administration of a 
32-rag IV dose of ondansetron (-722 nmol/L; calculated from P128 using MW 365.9 
and Cma x 264 ng/mL) also seem insufficient to produce significant blockade of 
sodium channels (based on the inhibition vs concentration curve for ondanse- 
tron; Figure). This is in contrast with dolasetron, inwhich plasma concentrations 
following the administration f a 100-mg IV dose (-730 nmol/L; calculated from 
P127 using MW 438.5 and Cma ~ 320 ng/mL) cause more sodium channel blockade 
compared with either ondansetron 32mg IV or granisetron 40 pg/kg IV (based on 
the inhibition vs concentration curve for hydrodolasetron; Figure). 
The Cma xvalues used to calculate plasma concentrations were from healthy 
volunteers, as documented in each drug's PI, rather than patients with cancer. 
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Figure. 
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Inhibitory effects of granisetron, ondansetron, and hydrodolasetron (the 
active metabolite of dolasetron) on cardiac sodium channels. Calculated ICs0 
values were 2.6 luM for granisetron, 88.5 IJM for ondansetron, and 8.5 IJM for 
dolasetron (hydrodolasetron). Cardiac sodium channel blockade by the Cma x 
values arising from specific doses of granisetron, ondansetron, and 
dolasetron have been predicted by superimposing their Cma x values onto a 
graph and reading from the respective curves. These calculations were based 
on the following: granisetron 40 [Jg/kg IV, molecular weight (MW) 348.9, 
Cma X 64.3 ng/mL29; ondansetron 32 mg IV, MW 365.9, Cma X 264 ng/mL28; 
dolasetron 100 mg IV, MW 438.5, Cma x 320 ng/mL. 27 INa = sodium channel 
current. Adapted with permission. 3
Cma x data are available from patients with cancer in the PI for dolasetron and 
granisetron but not for ondansetron 32 mg. The calculated plasma concentration 
following the administration of a 1.8-mg/kg dose of dolasetron is ~1152 nmol/L 
(calculated from P127 using MW 438.5 and Cm~ 505 ng/mL), which may produce 
even greater sodium channel blockade than suggested from the data obtained 
from healthy volunteers (Figure). In contrast, the plasma concentration fol- 
lowing the administration of granisetron 40 1Jg/kg IV in patients with cancer 
(182 nmol/L) is similar to that predicted in healthy volunteers (calculated from P129 
using MW 348.9 and Cma x63.8 ng/mL after administration f a 40-1Jg/kg IV dose). 
It should be noted, however, that we are comparing Cma x values in healthy vol- 
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unteers and patients with cancer with those from in vitro inhibition experi- 
ments conducted innoncancer cell lines (on which estimations ofsodium chan- 
nel blockade are based). 3 
Human ether-a-go-go-related gene (HERG) potassium channels are thought to 
be important for the repolarizing current in the human heart and are a determi- 
nant of the QT interval) Drugs that block potassium channels may produce QT 
prolongation, whereas drugs that block sodium hill channels may lead to 
widening of the QRS interval (which can prolong the QTc interval), 3 27 and in 
both cases ventricular arrhythmias may result. 3 The effects of dolasetron, 
ondansetron, and granisetron on the human cardiac potassium channels have 
also been investigated. 3 In those studies, the rank order of potency for these 
agents to block HERG potassium channels was ondansetron > granisetron >
dolasetron >hydrodolasetron, and the authors uggest that the reported pro- 
longation of cardiac repolarization observed with ondansetron 9,17 may be due 
to its ability to block the cardiac potassium channel. Although the reported 
changes in ECG intervals observed after administration f ondansetron 32 mg 
IV were transient and asymptomatic, 9,17 Kuryshev et al 3 predicted that high 
heart rates or other situations that favor activated states of the potassium 
channel may enhance the inhibition of the HERG channel by ondansetron. 3 
A review by Navari and Koeller 35 suggested that ECG interval changes are a 
class effect of the 5-HT3-receptor antagonists and that they possess only a small 
theoretical risk for meaningful cardiovascular events. However, it is argued that 
current evidence concerning ECG changes with 5-HT3-receptor antagonists sug- 
gests that, in clinical practice, QTc interval prolongation should be considered 
less of a "class effect" and more a "dose effect. ''36 As discussed by Navari and 
Koeller, 35 ECG changes caused by dolasetron use have been observed in healthy 
volunteers and in controlled trials, and their magnitude and frequency increased 
with dose. 27 In studies in healthy volunteers, dolasetron has resulted in signifi- 
cant dose-related, ose-dependent i creases in QTc interval. 9,16 Similarly, dose- 
related increases in QTc interval have been observed 1 to 2 hours following 
dolasetron administration in patients receiving chemotherapyJ 1,14 
Furthermore, the ECG changes associated with dolasetron use have been 
observed in clinical studies despite the fact that many patients who may be at 
increased risk for QTc interval prolongation (eg, patients with cardiac comor- 
bidities or irregularities, 4,7,1°-14 or those receiving certain antiarrhythmic med- 
ications 4,7,1°,11) were excluded. Moreover, given that patients with cancer are 
typically over the age of 65 years, 3° have a high incidence of cardiovascular 
comorbidities (~60% of patients aged >70 years37), and are likely to be consum- 
ing multiple medications, 31 there may be the potential for additive QT effects in 
patients with cancer already at risk for cardiovascular complications. 38,39 
When choosing a 5-HT3-receptor antagonist in a patient who has or may 
develop prolongation of cardiac conduction intervals, particularly QTc (includ- 
ing patients with hypokalemia, hypomagnesia, or congenital QT syndrome, or 
those receiving diuretics with the potential for inducing electrolyte abnormali- 
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ties, antiarrhythmic drugs or other drugs that might lead to QT prolongation, or 
cumulative high-dose anthracycl ine therapy), it would seem prudent o use an 
effective 5-HT3-receptor antagonist that has no warning or precaut ionary state- 
ments in its FDA labeling concerning prolongation of cardiac conduct ion inter- 
vals (including QTc prolongation). 
CONCLUSIONS 
This analysis of the FDA SRS/AERS database suggests a potential signal for ven- 
tricular arrhythmias and cardiac arrest with dolasetron, but not with ondansetron 
or granisetron. Although there are limitations to the PRR analysis, the presence 
of a potential signal for ventricular arrhythmias and cardiac arrestwith dolasetron 
suggests that further research into the potential signal may be necessary. 
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